Amarin Corp Plc - AMRN STOCK NEWS

Amarin Corporation plc (NASDAQ:AMRN) announced that Karim Mikhail, the president and CEO, will speak at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 9:00 a.m. ET. This event will take place in New York City from September 12-14, 2022. A live webcast of the presentation will be available here.

Amarin focuses on cardiovascular disease management and aims to advance treatments through scientific understanding.

Amarin Corporation (NASDAQ:AMRN) announced significant findings from its REDUCE-IT study, presented at the ESC Congress 2022. The data reveals that VASCEPA/VAZKEPA (icosapent ethyl) reduced first cardiovascular events by 23% in current smokers and 29% in former smokers compared to placebo. The incidence of cardiovascular events in current and former smokers using IPE was similar to that of never smokers. These results highlight the potential of IPE in mitigating cardiovascular risks associated with smoking history.

Amarin Corporation announced significant findings from the REDUCE-IT study presented at the ESC Congress 2022 in Barcelona. The study revealed that VASCEPA/VAZKEPA (icosapent ethyl) led to a 40% reduction in ST-segment elevation myocardial infarction (STEMI) and a 27% reduction in non-ST segment elevated myocardial infarction (NSTEMI) in patients with cardiovascular disease or diabetes. The study involved 8,179 patients and showed that IPE reduced the primary composite endpoint by 25% and the secondary endpoint by 26%. These results highlight the potential of IPE in managing cardiovascular risks.

Amarin Corporation plc (NASDAQ:AMRN) announced new research on VASCEPA/VAZKEPA's effects in cardiovascular patients accepted for presentation at the ESC Congress in Barcelona from August 26-29, 2022. Key findings include a Late-Breaking Science presentation on ST-segment Elevation MI reduction based on the REDUCE-IT trial. The data emphasizes VASCEPA's role in reducing cardiovascular risk, especially among high-risk groups, reinforcing findings from the REDUCE-IT study.

Amarin Corporation (NASDAQ:AMRN) announced a positive reimbursement decision for VAZKEPA from the UK’s NICE and initiated market access negotiations across Europe. The company aims for $100 million in cost savings over the next year in response to increasing competition. Q2 2022 net revenue was $94.4 million, down 39% from the previous year, primarily due to generic competition in the U.S. Amarin reported a net loss of $70 million. Despite challenges, the company is focused on expanding internationally and improving its financial position.

Scholar Rock (NASDAQ: SRRK) has appointed Dr. Srinivas Akkaraju, Founder and Managing General Partner at Samsara BioCapital, to its Board of Directors as an independent director. With over 20 years in biotechnology investment, Dr. Akkaraju brings extensive experience to the company as it develops its late-stage pipeline and discovery programs. His addition is anticipated to enhance Scholar Rock's strategic direction, particularly in advancing its therapeutic candidate for spinal muscular atrophy amid ongoing Phase 3 trials.

Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on August 3, 2022, at 8:00 a.m. ET to discuss its second quarter 2022 financial results, which will be released prior to the market opening. The call will be accessible through the Company’s investor relations website, and a replay will be available soon after. Amarin is advancing in cardiovascular disease management through clinical trials and commercial expansion, with offices in the U.S., Ireland, and Switzerland.

Amarin Corporation announced that NICE in the UK has finalized guidance recommending VAZKEPA® (icosapent ethyl) for reimbursement in England and Wales. This decision supports its use in reducing cardiovascular events in high-risk patients with elevated triglycerides. The approved price is £144.21 for a 30-day supply. Following this guidance, NHS formularies must make VAZKEPA available within 90 days in England and 60 days in Wales. This milestone is crucial for Amarin's European growth strategy and aims to unlock multi-billion-dollar revenue opportunities for VAZKEPA beyond the U.S.

Amarin Corporation announced a post hoc sub-analysis of the REDUCE-IT study, revealing that the majority of cardiovascular benefits from icosapent ethyl (IPE) stem from achieved eicosapentaenoic acid (EPA) levels. The study showed a 25% relative risk reduction in major adverse cardiovascular events (MACE). Despite small absolute changes in certain biomarkers, the substantial clinical benefit is attributed to a significant increase in EPA levels. The findings reinforce IPE's approval for ASCVD risk reduction, emphasizing its critical role in cardiovascular management.